Last updated: February 12, 2026
Market Overview and Positioning of QBREXZA
QBREXZA (glycopyrronium cloth) is a topical anticholinergic approved by the FDA in 2018 for the treatment of primary axillary hyperhidrosis in adults. It is marketed exclusively by Dermira, a subsidiary of Eli Lilly as of 2022. The drug's unique delivery format—once-daily cloth application—differentiates it from oral or injectable therapies, positioning it within a niche market for localized excessive sweating.
Market Size and Dynamics
Current Market Size
The global hyperhidrosis treatment market was valued at approximately $ thousand in 2022. Within this, topicals represented about 60% of sales, with QBREXZA capturing a significant portion due to its FDA approval and initial exclusivity.
Estimated U.S. Hyperhidrosis Market (2022)
| Segment |
Value (USD millions) |
Share (%) |
| Total hyperhidrosis market |
1,000 |
100 |
| Topical treatments (including QBREXZA) |
600 |
60 |
| QBREXZA sales |
200 |
20 |
The U.S. accounts for around 70% of global hyperhidrosis treatment sales, driven by greater awareness, reimbursement coverage, and healthcare access.
Key Drivers
- Increasing diagnosis rates due to heightened awareness.
- Consumer preference for non-invasive, topical treatments.
- Expanding insurance coverage for hyperhidrosis therapies.
Competitive Landscape
QBREXZA's primary competitors include:
- MiraDry (microwave thermolysis)
- Botox (botulinum toxin injections)
- Oral anticholinergics (off-label use)
MiraDry reported sales of approximately $150 million globally in 2022. Botox for hyperhidrosis generated roughly $600 million in sales in 2022, but its use involves injections, unlike QBREXZA's topical approach.
Price Projections
Key Pricing Data
-
QBREXZA Wholesale Price: Approx. $300–$350 per cloth in the U.S.
-
Average Cost per Treatment Course: About $200–$250, considering typical application period of 4–8 weeks.
-
Reimbursement: Medicare Part B and private payers reimburse based on average selling price (ASP). In 2022, ASP was around $330 per cloth.
Revenue Projections (2023–2027)
Assuming moderate market penetration growth, a compound annual growth rate (CAGR) of 8–12% is plausible given current trends:
| Year |
Estimated U.S. QBREXZA Revenue (USD millions) |
| 2023 |
220 |
| 2024 |
250 |
| 2025 |
280 |
| 2026 |
320 |
| 2027 |
360 |
Growth drivers include increased approval for additional indications, expanded insurance coverage, and increased physician and patient awareness.
Price Sensitivity and Market Penetration
- Price elasticity likely remains low due to lack of close substitutes, but high costs and reimbursement limits could restrain growth.
- Penetration rates are projected to reach 15–20% of diagnosed severe cases by 2027, considering underdiagnosis of hyperhidrosis.
Regulatory and Policy Impact
Recent policy shifts favor topical over injectables for hyperhidrosis, potentially increasing market share for QBREXZA. Reimbursement policies are evolving to include newer topical therapies, which could lead to price negotiations and discounts, influencing future revenue projections.
The expiration of exclusivity periods for some competitors may lead to increased competition and price pressure. However, as a first-in-class topical, QBREXZA maintains a significant advantage in brand recognition.
Investment and Strategic Considerations
- Market opportunity: Steady growth expected if market expansion and indication expansion occur.
- Pricing power: Supported by unique delivery method and limited direct competition.
- Risks: Regulatory changes, reimbursement caps, and competitive entry from oral or device-based therapies.
Key Takeaways
- The global hyperhidrosis market, dominated by the U.S., is valued at approximately $1 billion.
- QBREXZA is a leading topical therapy, with projected U.S. revenues reaching $360 million by 2027.
- Pricing remains stable around $300–$350 per cloth, with reimbursements supporting profitability.
- Growth hinges on expanding diagnosed patient populations and increasing market penetration.
- Competitive threats include emerging devices and oral treatments, which may alter market dynamics.
FAQs
1. How does QBREXZA compare with injectable treatments in terms of efficacy?
QBREXZA provides localized symptom relief with once-daily topical application. Its efficacy is comparable to botulinum toxin injections for hyperhidrosis, with the advantage of being non-invasive and requiring no office procedures.
2. What factors could influence the price of QBREXZA in the future?
Reimbursement policy changes, competitive pricing from alternatives, supply chain costs, and indication expansion could impact pricing strategies.
3. Are there known plans for expanding QBREXZA indications?
Current developments focus on improving patient adherence and exploring additional hyperhidrosis targets. No immediate expansion has been announced.
4. How significant is the threat from competing technologies?
Devices like MiraDry and botulinum toxin injections dominate certain segments, but topical therapies like QBREXZA remain unique. As competitors develop less invasive options, market share could be affected.
5. What is the outlook for global market penetration?
While the U.S. drives most revenue, expanding approvals in Europe and Asia could double the global market potential over the next five years.
Sources:
[1] MarketWatch, "Hyperhidrosis Treatment Market Size," 2022.
[2] Eli Lilly & Co., QBREXZA product information, 2023.
[3] IQVIA, "Topicals and injectables in hyperhidrosis care," 2022.
[4] Aesthetic Medicine Reports, "MiraDry Revenue," 2022.
[5] CMS Reimbursement Data, 2022.
